STOCKSCOPE

IDT Australia (ASX: IDT) Targets First Positive EBITDA as $50 Million Revenue Ambition Gains Momentum

Danny Aad

Danny Aad

Technology & Biotechnology Specialist | StockScope

Published:3d ago
IDT Australia (ASX: IDT) Targets First Positive EBITDA as $50 Million Revenue Ambition Gains Momentum

IDT Australia Limited (ASX: IDT) is approaching a significant financial milestone, forecasting a return to positive EBITDA in FY27 as its pharmaceutical manufacturing turnaround gathers momentum.

With improving cash flow, new long-term manufacturing contracts and a $50 million annual revenue target for FY29, the company is building a stronger foundation for growth. Its latest operating update highlights an encouraging shift from restructuring towards expanding revenue and operating profitability.

Key Numbers Behind IDT's Growth Outlook

  • $19 million to $20 million: FY27 core revenue guidance, representing projected growth of approximately 13% to 19%.
  • $1 million to $1.5 million: Forecast FY27 EBITDA, compared with a $922,000 loss in FY26.
  • $16.8 million: FY26 comparable core revenue, up 16.5% from $14.4 million in FY25.
  • $1.07 million: Positive FY26 operating cash flow, reversing a $6.25 million outflow in FY25.
  • $50 million: Targeted annual revenue by FY29, representing almost three times FY26 core revenue.

FY27 Guidance Points to an Important Earnings Breakthrough

IDT's 18 November 2026 operating update reinforces its improving financial outlook, with management expecting positive EBITDA for FY27.

The forecast represents a substantial improvement from FY26 and reflects the benefits of operational restructuring, growing manufacturing activity and a stronger customer pipeline.

Several major customer contracts are expected to commence during the second half of FY27, providing additional opportunities to expand revenue.

The company has also secured a five-year agreement with an existing radiopharmaceutical customer, strengthening its position in specialised pharmaceutical manufacturing.

Although the contract's financial value remains undisclosed, the longer-term relationship offers improved visibility over future manufacturing activity.

What Stands Out: Stronger Cash Flow and Operating Leverage

One of IDT's most encouraging developments is the improvement in its underlying financial performance.

FY26 EBITDA losses narrowed approximately 85%, from $6.3 million in FY25 to $922,000.

Importantly, the company also delivered $1.07 million in positive operating cash flow, compared with a $6.25 million outflow in the previous year.

This turnaround suggests IDT's operational improvements are beginning to translate into tangible financial benefits.

The company remains focused on improving profitability as manufacturing volumes increase, potentially allowing additional revenue to contribute more efficiently to earnings.

While FY26 statutory losses remained at $2.72 million and borrowings totalled approximately $10.82 million at 30 June 2026, improving operating cash generation provides a more constructive foundation for expansion.

What IDT Australia Is Doing Now

IDT is undertaking an approximately $7 million manufacturing upgrade programme at its Boronia facility in Victoria.

The investment is designed to expand sterile manufacturing capabilities, including production of pre-filled syringes and cartridges.

These upgrades position the company to pursue opportunities involving biologics, antibody drug conjugates, mRNA therapies and other specialised injectable treatments.

IDT is also strengthening its solid oral manufacturing capabilities to accommodate more complex pharmaceutical production requirements.

Its established relationships with pharmaceutical companies, including Sanofi, support its strategy of securing larger, longer-duration manufacturing programmes.

Together, these initiatives could improve facility utilisation, strengthen customer retention and create additional revenue opportunities.

Insight: Can IDT's Manufacturing Expansion Unlock Its Next Growth Phase?

We think IDT's improving financial performance and expanding manufacturing capabilities provide a promising foundation for its next growth phase. The transition towards positive EBITDA, combined with stronger operating cash flow and longer-term customer relationships, suggests its turnaround strategy is delivering measurable progress. Its specialised infrastructure and regulatory credentials also support a competitive position in pharmaceutical manufacturing. While achieving $50 million in annual revenue by FY29 remains ambitious, successful contract execution and improved capacity utilisation could strengthen the company's earnings profile. Sustained cash generation will be the key measure of success.

What Happens Next?

The second half of FY27 could prove particularly important as IDT begins delivering several larger manufacturing contracts.

Successful execution, increasing manufacturing volumes and continued improvements in operating cash flow would provide further evidence of the company's progress towards sustainable profitability.

The manufacturing upgrade programme also creates opportunities to pursue more sophisticated pharmaceutical contracts over the coming years.

Although additional funding requirements, project execution and contract timing remain considerations, IDT enters this next phase with improving operational momentum and a clearer earnings outlook.

With positive FY27 EBITDA now within management's expectations and a $50 million revenue ambition for FY29, IDT Australia is building a compelling longer-term manufacturing growth story.

Danny Aad

Danny Aad

(Technology & Biotechnology Specialist | StockScope)

Danny Aad is an experienced technology executive with a distinguished career spanning more than three decades, including senior leadership positions as Chief Technology Officer (CTO) across the technology and biotechnology sectors. With extensive expertise in technology strategy, digital innovation and the evolving biotechnology landscape, Danny brings a wealth of industry knowledge and technical insight to his analysis of emerging technologies, corporate developments and investment opportunities.

DisclaimerInformation on Stockscope is general in nature and does not constitute financial product advice. It does not take into account your personal objectives, financial situation or needs. Seek independent advice from a qualified financial adviser before making an investment decision. Stockscope and its affiliates do not guarantee the accuracy or completeness of information published on this website. To the extent permitted by law, they accept no liability for any claim, loss or damage arising from its use or reliance on it. Stockscope and its associates may have commercial relationships with companies featured on this website, hold securities in those companies, or receive commissions in connection with capital raisings.

Continue Reading

ASX slides to five-month low as AI sell-off rattles global markets
Market Briefings
Market Briefings

ASX slides to five-month low as AI sell-off rattles global markets

Australian equities: what moved the ASX 200? Australian shares extended their losing streak on Friday, with the S&P/ASX 200 falling 137.8 points, or 1.58%, to close at 8,592.6. This marked...

Mark ElzayedMark Elzayed•
NEXTDC (ASX: NXT) Raises FY27 Earnings Outlook as $140 Million Melbourne Opportunity Remains in Play
Technology
Technology

NEXTDC (ASX: NXT) Raises FY27 Earnings Outlook as $140 Million Melbourne Opportunity Remains in Play

NEXTDC Limited ASX: NXT has delivered an encouraging upgrade to its FY27 earnings guidance, highlighting the strength of its broader data centre business despite electricity supply delays at...

Danny AadDanny Aad•
Trek Metals (ASX: TKM) Hits 40.3% Manganese at Kuro as High-Grade Discovery Opens Up Bigger Potential
Mining
Mining

Trek Metals (ASX: TKM) Hits 40.3% Manganese at Kuro as High-Grade Discovery Opens Up Bigger Potential

A standout 25-metre intersection grading 31.4% manganese has delivered another encouraging result for Trek Metals Limited ASX: TKM, strengthening the exploration potential of its Kuro discov...

Alison ElzayedAlison Elzayed•
EBR Systems (ASX: EBR) Moves Closer to US-Wide Medicare Coverage as Major Growth Opportunity Emerges
Biotech & Health
Biotech & Health

EBR Systems (ASX: EBR) Moves Closer to US-Wide Medicare Coverage as Major Growth Opportunity Emerges

EBR Systems ASX: EBR has taken another significant step towards expanding the commercial reach of its wireless heart pacing technology, with US Medicare authorities proposing national covera...

Danny AadDanny Aad•
Orion Minerals (ASX: ORN) Unlocks US$6.7 Million From Glencore as Major Copper Production Milestone Approaches
Mining
Mining

Orion Minerals (ASX: ORN) Unlocks US$6.7 Million From Glencore as Major Copper Production Milestone Approaches

Orion Minerals ASX: ORN has reached a significant turning point in its copper and zinc development strategy, receiving its first US$6.7 million payment from global mining group Glencore. The...

Alison ElzayedAlison Elzayed•
EMVision Medical Devices (ASX: EMV) Unlocks a 1,700-Hospital Opportunity as Fresh Funding Accelerates Stroke Scanner Development
Biotech & Health
Biotech & Health

EMVision Medical Devices (ASX: EMV) Unlocks a 1,700-Hospital Opportunity as Fresh Funding Accelerates Stroke Scanner Development

EMVision Medical Devices ASX: EMV is building momentum towards a potentially significant commercial breakthrough, with a fresh $306,750 government grant payment supporting the expansion of i...

Danny AadDanny Aad•
Loading more stories...